NEW YORK: Pfizer reported a jump in second-quarter profits on Thursday behind a near doubling of revenues driven by sales of its COVID-19 vaccine and therapeutic drug Paxlovid.
US officials last month approved emergency authorisation to Pfizer and Moderna for COVID-19 vaccines in under-five-year-olds, the final age group awaiting immunisation in most countries.
Resumimos esta notícia para que você possa lê-la rapidamente. Se você se interessou pela notícia, pode ler o texto completo aqui. Consulte Mais informação: